With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA

Lilly’s Oral GLP-1 Also Impressed

 
• By Mandy Jackson

Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% weight loss at 36 weeks in Phase II without reaching a plateau. 

Measuring tape on a wood background
Novo's oral semaglutide measures up well with Wegovy in obesity • Source: Shutterstock

More from Clinical Trials

More from R&D